Lexicon Pharmaceuticals Reports $28.9M Revenue Surge in Q2 2025

Lexicon Pharmaceuticals, Inc. reported a significant increase in its financial performance for the second quarter of 2025, with total revenues reaching approximately $28.9 million, compared to $1.6 million in the same period of 2024. This surge was primarily driven by $27.5 million in licensing revenue from a recent agreement with Novo Nordisk for the development of LX9851, a drug candidate for obesity and cardiometabolic disorders. The company also generated $1.3 million in net product revenue from its approved drug, INPEFA® (sotagliflozin), which has been commercially available since May 2023. For the first half of 2025, total revenues amounted to $30.1 million, up from $2.8 million in the prior year.

In terms of profitability, Lexicon reported a net income of $3.3 million, or $0.01 per diluted share, for the second quarter of 2025, a stark contrast to the net loss of $53.4 million, or $0.17 per share, recorded in the same quarter of 2024. The company’s operating expenses also saw a notable decline, totaling $25.1 million for the second quarter, down from $57.0 million in the previous year. This reduction was largely attributed to decreased selling, general, and administrative expenses, which fell by 76% to $9.4 million, reflecting a restructuring that reduced headcount and associated costs.

Operationally, Lexicon has made strategic advancements, including the exclusive licensing agreement with Novo Nordisk, which not only provided an upfront payment of $45 million but also positions the company for potential future milestone payments totaling up to $485 million, along with tiered royalties on net sales. Additionally, Lexicon continues to develop its drug candidates, including pilavapadin for neuropathic pain and ongoing efforts to secure regulatory approval for ZYNQUISTA® (sotagliflozin) for type 1 diabetes.

As of June 30, 2025, Lexicon's total assets were reported at $225.6 million, a decrease from $298.4 million at the end of 2024, primarily due to a reduction in cash and cash equivalents, which fell to $21.4 million from $66.7 million. The company’s liabilities also decreased significantly, totaling $96.1 million compared to $152.5 million at the end of the previous year. The reduction in liabilities was influenced by a $45 million repayment of debt in April 2025, part of a broader restructuring of its financing arrangements.

Looking ahead, Lexicon anticipates continued investment in research and development, particularly for its drug candidates, while also managing its cash flow to support ongoing operations. The company believes its current cash and investment balances, along with expected revenues from collaborations, will be sufficient to fund operations for at least the next 12 months. However, Lexicon acknowledges the need for additional financing in the future to support its growth and development initiatives, which may involve selling equity or securing new credit arrangements.